Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized Regorafenib Dosing in Metastatic Colorectal Cancer
2024-517241-13-00Phase 2Completed
- Sponsor
- CHU Rennes
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of regorafenib in metastatic colon cancer (mCRC), sponsored by CHU Rennes. Primary endpoint: Overall survival by exposure group. Started Sep 2024; status: completed.
02
Drugs
regorafenib
03
Conditions
metastatic colon cancer (mCRC)
Beyond the preview
Go deeper on 2024-517241-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517241-13-00.